Updated Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κb Activation
| Autor: | Daher, May, Hidalgo Lopez, Juliana Elisa, Randhawa, Jasleen K., Jabbar, Kausar Jabeen *, Pemmaraju, Naveen, Borthakur, Gautam, Kadia, Tapan M., Konopleva, Marina, Kantarjian, Hagop M., Cortes, Jorge E., Hearn, Katherine P. *, Reyes, Steven R. *, Bueso-Ramos, Carlos E., Garcia-Manero, Guillermo |
|---|---|
| Zdroj: | In Blood 2 December 2016 128(22):3191-3191 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|